|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02096 SIMCERE PHARMA
Nominal 
8.660 +0.260 (+3.095%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 6,635,211 | 0.415% | 6,607,805 | 6,324,082 | 4,999,718 | 4,508,720 |
| Cost of Sales | (1,310,632) | -19.279% | (1,623,652) | (1,327,404) | (1,079,983) | (899,927) |
| Gross Profit | 5,324,579 | 6.830% | 4,984,153 | 4,996,678 | 3,919,735 | 3,608,793 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 2,162 | -72.438% | 7,844 | 190 | (44,186) | (14,267) | |
| Profit / (Loss) before Taxation | 819,878 | 10.789% | 740,038 | 886,254 | 1,401,797 | 805,088 | |
| Taxation | (86,713) | 232.387% | (26,088) | 40,478 | 97,124 | (140,801) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 811 | 4,136 | 8,175 | 5,247 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 733,165 | 2.575% | 714,761 | 930,868 | 1,507,096 | 669,534 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 30,331 | -- | (20,392) | (25,459) | 2,561 | 107,481 |
| Depreciation & Amortisation | 337,647 | 9.061% | 309,594 | 283,647 | 251,807 | 222,329 |
| Directors' Emoluments | -- | -- | 34,084 | 35,451 | 21,726 | 23,723 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 29.000 | 7.407% | 27.000 | 36.000 | 58.000 | 28.000 |
| DPS (cts) | 16.000 | -- | 16.000 | 16.000 | 15.000 | 15.000 |
| Dividend Payout Ratio (%) | 55.172% | -- | 59.259% | 44.444% | 25.862% | 53.571% |
| Cash flow per share ($) | -- | -- | 0.058 | 0.519 | (0.077) | 0.040 |
| NBV per share ($) | 2.797 | -- | 2.745 | 2.681 | 2.449 | 2.032 |
| Remarks: | Real time quote last updated: 03/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 733,165 |
| %Change | 2.575% |
| EPS / (LPS) | RMB 0.290 |
| NBV Per Share (¥) | RMB 2.797 |